Alphatec Holdings, Inc. (“ATEC” or the “Company”) (Nasdaq: ATEC), a
provider of innovative spine surgery solutions dedicated to
revolutionizing the approach to spine surgery, today announced
financial results for the quarter ended March 31, 2019, and recent
corporate highlights.
First Quarter 2019 Financial
Highlights
- Total net revenue of $24.6 million; U.S. product revenue
of $23.0 million, up approximately 20% compared to the first
quarter of 2018;
- U.S. commercial gross margin of 71.4%;
- Cash and cash equivalents of $16.4
million at March 31, 2019; and
- Additional capital commitment of up to $30 million from
Squadron Capital.
Year-to-Date Commercial, Product, and
Organizational Highlights
- Enhanced clinical distinction of portfolio via 3 new commercial
releases: the IdentiTi™ ACDF system, the IdentiTi™ PLIF
system, and AlphaGRAFT® DBM Fiber;
- Received FDA clearance for SafeOp Advanced Automated
Neuromonitoring System and affirmed performance through
collaboration with key surgeon partners;
- Drove contribution from new products to 22% of Q1 2019 U.S.
revenue on strong acceptance of alpha releases;
- Expanded contribution from strategic distribution network to
84% of U.S. revenue in Q1 2019 compared to 72% in Q1 2018;
- Increased revenue per distributor by more than 30% and
increased revenue per case by 13% in Q1 2019 compared to Q1 2018;
and
- Strengthened distribution network through promotion of David
Sponsel to Head of Sales.
“Financial results in the first quarter have
begun to more fully reflect the grit and tenacity of the new ATEC,”
said Pat Miles, Chairman and Chief Executive Officer. “On the
success of last year’s alpha launches, first quarter U.S. revenue
growth accelerated to 20% year-over-year, our second consecutive
quarter of double-digit growth. As we continue to
commercially launch the twelve new products slated for 2019 and
leverage the high-caliber sales leadership team and professional
distribution network we are building, we expect surgeon adoption to
accelerate. While we still have a great deal of work to do and are
early in the transformation, we are incredibly excited to unleash
the full effect of the ATEC organic innovation machine.”
Comparison of Financial Results for the
First Quarter 2019 to First Quarter 2018
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Change |
|
March 31, 2019 |
|
March 31, 2018 |
|
$ |
|
% |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from U.S. products |
$ |
22,955 |
|
|
$ |
19,201 |
|
|
$ |
3,754 |
|
|
20 |
% |
Gross profit from U.S.
products |
|
16,394 |
|
|
|
14,767 |
|
|
|
1,627 |
|
|
11 |
% |
Gross margin from U.S.
products |
|
71.4 |
% |
|
|
76.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
Research and development |
$ |
3,469 |
|
|
$ |
1,786 |
|
|
$ |
1,683 |
|
|
94 |
% |
Sales, general and administrative |
|
21,000 |
|
|
|
17,257 |
|
|
|
3,743 |
|
|
22 |
% |
Litigation-related expenses |
|
2,623 |
|
|
|
580 |
|
|
|
2,043 |
|
|
352 |
% |
Amortization of intangible assets |
|
182 |
|
|
|
177 |
|
|
|
5 |
|
|
3 |
% |
Transaction-related expenses |
|
- |
|
|
|
1,542 |
|
|
|
(1,542 |
) |
|
(100 |
%) |
Gain on settlement |
|
- |
|
|
|
(6,168 |
) |
|
|
6,168 |
|
|
(100 |
%) |
Restructuring |
|
60 |
|
|
|
398 |
|
|
|
(338 |
) |
|
(85 |
%) |
Total operating expenses |
$ |
27,334 |
|
|
$ |
15,572 |
|
|
$ |
11,762 |
|
|
76 |
% |
|
|
|
|
|
|
|
|
Operating loss |
$ |
(10,766 |
) |
|
$ |
(667 |
) |
|
$ |
(10,099 |
) |
|
1514 |
% |
|
|
|
|
|
|
|
|
Non-GAAP operating loss |
$ |
(4,206 |
) |
|
$ |
(2,778 |
) |
|
$ |
(1,428 |
) |
|
51 |
% |
|
|
|
|
|
|
|
|
Non-GAAP adjusted EBITDA |
$ |
(2,421 |
) |
|
$ |
(892 |
) |
|
$ |
(1,529 |
) |
|
171 |
% |
|
|
|
|
|
|
|
|
Revenue from U.S. products for the first quarter 2019 was $23.0
million, up 20% compared to $19.2 million in the first quarter
2018. Revenue growth generated by the strategic distribution
channel is increasingly offsetting the continued revenue impacts
associated with transitioning or discontinuing non-strategic
distributor relationships.
Gross profit and gross margin from U.S. products
for the first quarter 2019 were $16.4 million and 71.4%,
respectively, compared to $14.8 million and 76.9%, respectively,
for the first quarter 2018. U.S. gross margin was pressured by
increased non-cash excess and obsolete write-offs related to legacy
products.
Total operating expenses for the first quarter
2019 were $27.3 million, compared to $15.6 million in the first
quarter 2018. On a non-GAAP basis, excluding restructuring
charges, stock-based compensation, transaction-related expenses,
litigation-related expenses, one-time gains and fair value
adjustments, total operating expenses in the first quarter 2019
increased to $22.8 million from $18.6 million in 2018, reflecting
increased investments in organic product development to support new
product launches and increased selling costs from U.S. revenue
growth.
Operating loss for the first quarter 2019 was
$10.8 million, compared to $0.7 million in the first quarter 2018.
On a non-GAAP basis, excluding restructuring charges, stock-based
compensation, transaction-related expenses, litigation-related
expenses, one-time gains, fair value adjustments and non-cash
excess and obsolescence charges, operating loss was $4.2 million
for the first quarter 2019, compared to a loss of $2.8 million for
the first quarter 2018.
Non-GAAP adjusted EBITDA in the first quarter
was a loss of $2.4 million, compared to a loss of $0.9 million in
the first quarter 2018.
For more detailed information on non-GAAP
operating loss and non-GAAP adjusted EBITDA, please refer to the
table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP
Financial Measures,” that follows.
Current and long-term debt includes $35.0
million in term debt and $10.6 million outstanding under the
Company’s revolving credit facility at March 31, 2019, with cash
and cash equivalents of $16.4 million. In March 2019, the Company
closed its expanded credit facility with Squadron Medical Finance
Solutions, providing for up to $30 million in additional financing,
as needed. To date, no amounts have been drawn on the new credit
facility.
2019 Financial Outlook
ATEC expects total revenue in 2019 of $98.0
million to $103.0 million. The Company expects U.S. product
revenue of $94.0 million to $98.0 million, reflecting growth of 13%
to 17% compared to 2018.
Investor Conference Call
ATEC will present the results via a live webcast
today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. At
that time, please click here to access the live webcast. An
audiocast of the presentation will be also be available
domestically at (877) 556-5251 and internationally at (720)
545-0036. The conference ID number is 7137619.
Non-GAAP Financial
Information
To supplement the Company’s financial statements
presented in accordance with U.S. generally accepted accounting
principles (GAAP), the Company reports certain non-GAAP financial
measures. The Company believes that these non-GAAP financial
measures provide investors with an additional tool for evaluating
the Company's core performance, which management uses in its own
evaluation of continuing operating performance, and a baseline for
assessing the future earnings potential of the Company. The
Company’s non-GAAP financial measures may not provide information
that is directly comparable to that provided by other companies in
the Company’s industry, as other companies in the industry may
calculate non-GAAP financial results differently, particularly
related to non-recurring, unusual items. Non-GAAP financial results
should be considered in addition to, and not as a substitute for,
or superior to, financial measures calculated in accordance with
GAAP. Included below are reconciliations of the non-GAAP financial
measures to the comparable GAAP financial measures.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its
wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp
Surgical, Inc., is a provider of innovative spine surgery solutions
dedicated to revolutionizing the approach to spine surgery. ATEC
designs, develops and markets spinal fusion technology products and
solutions for the treatment of spinal disorders associated with
disease and degeneration, congenital deformities and trauma.
The Company markets its products in the U.S. via independent sales
agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to the
Company’s revenue and growth outlook, planned commercial launches
and product introductions, the Company’s strategy in significantly
repositioning the ATEC brand, turning the Company into a growth
organization and creating future market disruption, and the
Company’s future ability to finance its operations. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the
uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community; failure to obtain FDA or other
regulatory clearance or approval for new products, or unexpected or
prolonged delays in the process; continuation of favorable third
party reimbursement for procedures performed using the Company’s
products; unanticipated expenses or liabilities or other adverse
events affecting cash flow or the Company’s ability to successfully
control its costs or achieve profitability; uncertainty of
additional funding; the Company’s ability to compete with other
products and with emerging new technologies; product liability
exposure; an unsuccessful outcome in any litigation in which the
Company is a defendant; patent infringement claims; claims related
to the Company’s intellectual property and the Company’s ability to
meet its financial obligations under its credit agreements and
the OrthoTec LLC settlement agreement. The words “believe,”
“will,” “should,” “expect,” “intend,” “estimate,” “look forward”
and “anticipate,” variations of such words and similar expressions
identify forward-looking statements, but their absence does not
mean that a statement is not a forward-looking statement. A
further list and description of these and other factors, risks and
uncertainties can be found in the Company's most recent annual
report, and any subsequent quarterly and current reports, filed
with the Securities and Exchange Commission. ATEC disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
|
|
|
Investor/Media Contact: |
|
Company Contact: |
|
|
|
Tina Jacobsen |
|
Jeff Black |
Investor Relations |
|
Chief Financial Officer |
(760) 494-6790 |
|
ir@atecspine.com |
ir@atecspine.com |
|
|
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share
amounts - unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
March 31, |
|
|
|
2019 |
|
|
|
2018 |
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
Revenue from U.S. products |
$ |
22,955 |
|
|
$ |
19,201 |
|
|
Revenue from international supply agreement |
|
1,600 |
|
|
|
2,106 |
|
|
Total revenues |
|
24,555 |
|
|
|
21,307 |
|
|
Cost of revenues |
|
7,987 |
|
|
|
6,402 |
|
|
Gross profit |
|
16,568 |
|
|
|
14,905 |
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
Research and development |
|
3,469 |
|
|
|
1,786 |
|
|
Sales, general and administrative |
|
21,000 |
|
|
|
17,257 |
|
|
Litigation-related expenses |
|
2,623 |
|
|
|
580 |
|
|
Amortization of intangible assets |
|
182 |
|
|
|
177 |
|
|
Transaction-related expenses |
|
- |
|
|
|
1,542 |
|
|
Gain on settlement |
|
- |
|
|
|
(6,168 |
) |
|
Restructuring expenses |
|
60 |
|
|
|
398 |
|
|
Total operating expenses |
|
27,334 |
|
|
|
15,572 |
|
|
Operating loss |
|
(10,766 |
) |
|
|
(667 |
) |
|
Total other income (expense), net |
|
(2,119 |
) |
|
|
(1,645 |
) |
|
Loss from continuing
operations before taxes |
|
(12,885 |
) |
|
|
(2,312 |
) |
|
Income tax (benefit) provision |
|
31 |
|
|
|
(458 |
) |
|
Loss from continuing
operations |
|
(12,916 |
) |
|
|
(1,854 |
) |
|
Loss from discontinued operations |
|
(52 |
) |
|
|
(62 |
) |
|
Net loss |
$ |
(12,968 |
) |
|
$ |
(1,916 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share,
basic: |
|
|
|
|
Continuing operations |
$ |
(0.29 |
) |
|
$ |
(0.09 |
) |
|
Discontinued operations |
|
(0.00 |
) |
|
|
(0.00 |
) |
|
Net loss per share, basic and
diluted |
$ |
(0.29 |
) |
|
$ |
(0.09 |
) |
|
Shares used in calculating basic and diluted net loss per
share |
|
|
|
|
|
45,020 |
|
|
|
21,212 |
|
|
|
|
|
|
|
Stock-based
compensation included in: |
|
|
|
|
Cost of revenue |
$ |
28 |
|
|
$ |
22 |
|
|
Research and development |
|
462 |
|
|
|
(116 |
) |
|
Sales, general and
administrative |
|
1,122 |
|
|
|
713 |
|
|
|
$ |
1,612 |
|
|
$ |
619 |
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
(in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
December 31, |
|
|
2019 |
|
2018 |
|
|
(Unaudited) |
|
|
|
ASSETS |
|
Current assets: |
|
|
|
|
Cash |
$ |
16,419 |
|
$ |
29,054 |
|
Accounts receivable, net |
|
13,760 |
|
|
15,095 |
|
Inventories, net |
|
31,166 |
|
|
28,765 |
|
Prepaid expenses and other current assets |
|
2,167 |
|
|
2,380 |
|
Current assets of discontinued operations |
|
237 |
|
|
242 |
|
Total current assets |
|
63,749 |
|
|
75,536 |
|
|
|
|
|
|
Property and equipment,
net |
|
12,821 |
|
|
13,235 |
|
Right-of-use asset |
|
2,394 |
|
|
- |
|
Goodwill |
|
13,897 |
|
|
13,897 |
|
Intangibles, net |
|
26,226 |
|
|
26,408 |
|
Other assets |
|
277 |
|
|
347 |
|
Noncurrent assets of
discontinued operations |
|
53 |
|
|
54 |
|
Total assets |
$ |
119,417 |
|
$ |
129,477 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
Current liabilities: |
|
|
|
|
Accounts payable |
$ |
6,780 |
|
$ |
4,399 |
|
Accrued expenses |
|
18,527 |
|
|
22,316 |
|
Current portion of long-term debt |
|
619 |
|
|
3,276 |
|
Current portion of lease liability |
|
1,132 |
|
|
- |
|
Current liabilities of discontinued operations |
|
569 |
|
|
621 |
|
Total current liabilities |
|
27,627 |
|
|
30,612 |
|
|
|
|
|
|
|
|
|
|
|
Total long term liabilities |
|
58,937 |
|
|
57,688 |
|
|
|
|
|
|
Redeemable preferred stock |
|
23,603 |
|
|
23,603 |
|
Stockholders' equity |
|
9,250 |
|
|
17,574 |
|
Total liabilities and
stockholders' equity |
$ |
119,417 |
|
$ |
129,477 |
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES |
(in thousands -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2019 |
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
27,334 |
|
|
|
15,572 |
|
|
Adjustments: |
|
|
|
|
|
Stock-based compensation |
|
|
(1,584 |
) |
|
|
(597 |
) |
|
Contingent consideration fair value adjustment |
|
|
(289 |
) |
|
|
- |
|
|
Litigation-related expenses |
|
|
(2,623 |
) |
|
|
(580 |
) |
|
Restructuring |
|
|
(60 |
) |
|
|
(398 |
) |
|
Transaction-related expenses |
|
|
- |
|
|
|
(1,542 |
) |
|
Gain on settlement |
|
|
- |
|
|
|
6,168 |
|
|
Non-GAAP operating
expenses |
|
$ |
22,778 |
|
|
$ |
18,623 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2019 |
|
2018 |
|
|
|
|
|
|
|
Operating loss, as
reported |
|
$ |
(10,766 |
) |
|
$ |
(667 |
) |
|
Add back significant
items: |
|
|
|
|
|
Stock-based compensation |
|
|
1,612 |
|
|
|
619 |
|
|
Contingent consideration fair value adjustment |
|
|
289 |
|
|
|
- |
|
|
Litigation-related expenses |
|
|
2,623 |
|
|
|
580 |
|
|
Restructuring |
|
|
60 |
|
|
|
398 |
|
|
Transaction-related expenses |
|
|
- |
|
|
|
1,542 |
|
|
Excess & obsolescence charges |
|
|
1,976 |
|
|
|
918 |
|
|
Gain on settlement |
|
|
- |
|
|
|
(6,168 |
) |
|
Adjusted operating loss |
|
|
(4,206 |
) |
|
|
(2,778 |
) |
|
|
|
|
|
|
|
Add back: |
|
|
|
|
|
Depreciation |
|
|
1,603 |
|
|
|
1,592 |
|
|
Amortization of intangible assets |
|
|
182 |
|
|
|
294 |
|
|
Adjusted EBITDA |
|
$ |
(2,421 |
) |
|
$ |
(892 |
) |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES AND GROSS
PROFIT |
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
March 31, |
|
|
2019 |
|
2018 |
|
Revenues by source |
|
|
|
|
Revenue from U.S. products |
$ |
22,955 |
|
|
$ |
19,201 |
|
|
Revenue from international
supply agreement |
|
1,600 |
|
|
|
2,106 |
|
|
Total revenues |
$ |
24,555 |
|
|
$ |
21,307 |
|
|
|
|
|
|
|
Gross profit by source |
|
|
|
|
Revenue from U.S.
products |
$ |
16,394 |
|
|
$ |
14,767 |
|
|
Revenue from international
supply agreement |
|
174 |
|
|
|
138 |
|
|
Total gross profit |
$ |
16,568 |
|
|
$ |
14,905 |
|
|
|
|
|
|
|
Gross profit margin by
source |
|
|
|
|
Revenue from U.S.
products |
|
71.4 |
% |
|
|
76.9 |
% |
|
Revenue from international
supply agreement |
|
10.9 |
% |
|
|
6.6 |
% |
|
Total gross profit margin |
|
67.5 |
% |
|
|
70.0 |
% |
|
|
|
|
|
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024